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BACKGROUND: Metastasis is associated with poor prognosis for melanoma. The formation of metastases is a multi-step process, in
which cancer cells can subsequently acquire the potential to intravasate into the blood or lymph vessels, disseminate through the
circulation, extravasate through the endothelium and invade the connective tissue. There is increasing evidence that chemokines have
a pivotal role in the dissemination and establishment of melanoma metastasis.
METHODS: We isolated melanoma cells from melanoma metastasis and performed different migration assays and transendothelial
resistance measurements of endothelial monolayers co-cultured with melanoma cells, in order to monitor barrier function and
diapedesis and confirmed these results by confocal microscopy.
RESULTS: We observed that tumour endothelial cells (ECs) secrete high levels of CXCL9 in all, and CXCL10 in most melanoma
metastases. Migration studies revealed that low concentrations of these chemokines induce chemotaxis, whereas high concentrations
induce spontaneous migration of melanoma cells (chemokinesis/chemorepulsion) and the disruption of the endothelial barrier,
resulting in an accelerated transendothelial migration (TEM). Addition of anti-CXCL9 or anti-CXCR3 antibodies to the co-cultures
delayed the TEM of melanoma cells.
CONCLUSION: Our data represent novel mechanisms by which tumour cells in melanoma metastases might use the chemokine-
expressing endothelium to leave the tumour and eventually to form additional metastases at distinct sites.
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Cancer cell invasion and metastasis are the primary causes of
morbidity and mortality in human cancer. The development of
malignant melanoma is a multi-step process including prolifera-
tion, differentiation, infiltration, intravasation into the lymph or
bloodstream, survival, extravasation, invasion as well as adhesion
and proliferation in distinct organ microenvironments (Hanahan
and Weinberg, 2000). One of the rate-limiting steps in metastasis
formation is the transendothelial migration (TEM) of the
melanoma cells, which involves their adhesion to and subsequent
transmigration through the endothelial cell (EC) monolayer
(Sandig et al, 1997; Voura et al, 1998, 2001; Weis et al, 2004;
Qi et al, 2005). Besides specific adhesion molecules, soluble factors
such as growth factors, cytokines and chemokines are necessary to
facilitate the extravasation process of the melanoma cells (Li and
Zhu, 1999; Simiantonaki et al, 2002; Ramjeesingh et al, 2003).
Chemokines are small-protein signalling molecules that have a
versatile and controversial role in tumour formation. Many
chemokines show an antitumour effect by attracting immune cells
to the tumour or by anti-angiogenic activity. By contrast, other
chemokines may enhance tumour growth by acting as angiogenic
factors, by stimulating proliferation of the tumour cells or by
attracting tumour cells to a specific site (Rollins, 1997; Mu ¨ller et al,
2001; Robledo et al, 2001; Wiley et al, 2001; Kawada et al, 2004).
Chemokines that are found in the tumour environment, produced
mainly by activated macrophages, are the CXCR3 ligands CXCL9/
MIG and CXCL10/IP-10, attracting CXCR3-expressing T-cells and
natural killer cells (Loetscher et al, 1996; Kunz et al, 1999;
Romagnani et al, 2001a,b; Payne and Cornelius, 2002). Numerous
other chemokines, such as CXCL8 or CCL5, and chemokine
receptors, such as CXCR4, CCR10 or CCR7, have been demon-
strated to be expressed by melanoma cells (Payne and Cornelius,
2002).
In this study, we observed that the chemokine CXCL9 is highly
secreted by tumour endothelial cells (TuECs) in melanoma
metastases and that CXCR3 receptors are expressed on all isolated
melanoma cells, regardless the tissue from which the metastasis
was surgically removed. Low concentrations of the chemokine
CXCL9 have a chemoattractive effect, whereas high concentrations
have a repulsive effect on the melanoma cells. Stimulation with
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tion of the melanoma cells through an endothelial monolayer.
Furthermore, pretreatment with CXCL9 increases the disruption of
endothelial cell–cell contacts when the EC monolayer is brought in
close contact with the melanoma cells.
MATERIALS AND METHODS
Biochemicals and antibodies
Soluble human CXCL9 was purchased from PreproTech Inc.,
Rocky Hill, NJ, USA. Purified non-labelled mouse monoclonal
antibodies were anti-CXCL9, anti-CXCR3, anti-CD31, (R&D
Systems, McKinley Place, MN, USA) and Isotype IgG (Sigma-
Aldrich, St Louis, MO, USA). FITC-conjugated anti-CXCR3 mAb
and biotinylated goat IgG anti-human CD144 were purchased from
R&D Systems, PE-conjugated anti-CD34 from BD Biosciences
(San Jose, CA, USA) and PC5-conjugated anti-CD144 from
Immunotech (Marseille, France). Lymphatic vessel-specific anti-
podoplanin Ab was generated as described (Kriehuber et al, 2001).
Cell culture
Human lymphatic endothelial cells (LECs) were obtained from
ATCC (Manassas, VA, USA) and immortalised by ectopic
expression of telomerase reverse transcriptase. Human umbilical
vein endothelial cells (HUVECs) were obtained from PromoCell
(Mannheim, Germany).
Isolation of melanoma cells from metastatic melanoma
Metastatic melanoma (Supplementary Table I) with clear
morphological discrimination to surrounding tissue was homo-
genised by cutting and treated with dispase (Invitrogen Life
Technologies, Carlsbad, CA, USA) for 20min at 371C. Cells were
seeded into fibronectin-coated (10mgml
 1; Sigma, Taufkirchen,
Germany) wells and cultured in RPMI-1640 medium with 10%
FCS, antibiotics and glutamine.
Isolation of TuECs
Melanoma metastases were finely minced and incubated in
Collagenase IV (0.5Uml
 1, Worthington, Freehold, NJ, USA) for
90min at 371C. After vigorous agitation, cells were pressed through
a cell dissociation sieve (Sigma-Aldrich), accompanied by ex-
tensive washing with cold RPMI (10% FCS). Cells were centrifuged
and stained with anti-CD144 for immunomagnetic enrichment of
ECs using anti-IgG1 immunomagnetic beads (Miltenyi Biotec,
Auburn, CA, USA). Enriched cell suspensions were incubated with
PE-conjugated anti-CD34 and anti-podoplanin (anti-rabbit Alexa-
488; Molecular Probes, Eugene, OR, USA). Cells were sorted using
the FACSAria (BD Biosciences) to a purity of at least 98%.
Isolation of ECs from normal skin
The skin was obtained from healthy adults undergoing elective
plastic surgery. Dermal sheets were prepared by incubation of
split-thickness skin (0.8mm) with DispaseI (3Uml
 1; Roche,
Mannheim, Germany) for 60min at 371C, and subsequent removal
of the epidermis. Endothelial cells were released from the tissue by
scraping, enriched and sorted as described above.
All human tissue specimens were obtained upon informed
consent. All samples of melanoma metastases were collected at the
General Hospital Vienna following approval by an Institutional
Review Board and written informed consent (patient ID: N, normal
skin, T, tumour metastases).
Quantitative real-time PCR
Total RNA was extracted using the High Pure RNA Isolation Kit
(Roche). RNA was reverse transcribed with the TaqMan 50 nuclease
RT–PCR assay (Applied Biosystems, Foster City, CA, USA).
TaqMan primer and probe sequences for B2M (internal control),
CXCL9 and CXCL10 were purchased commercially (Applied
Biosystems). Reactions were run on a spectrofluorometric thermal
cycler (MX 4000; Stratagene, La Jolla, CA, USA). Threshold cycle
(Ct) values of the target genes were converted to arbitrary
expression values by extrapolation from the standard curve and
finally normalised to the internal control.
Cloning of CXCL9 and expression vectors
RNA was isolated from interferon-g (Invitrogen, Life Technologies)-
stimulated HUVECs using the RNeasy kit, (Qiagen, Hilden,
Germany). After DNaseI treatment, 1mgt o t a lR N A ,o l i g o ( d T ) 15
pimer and reverse transcriptase (Roche) was used for RT–PCR
and CXCL9: forward primer, 50-aggagtgacttggaactccatt-30;r e v e r s e
primer, 50-tggggacaagatgagaaagg-30 for PCR reaction (MyCycler,
Bio-Rad, Richmond, CA, USA). CXCL9 DNA was cloned into
pIRES-EGFP vector by blunt end cloning.
Cell transfections
Endothelial cells (4 10
5) per well were transfected by the
lipofectamin-2000 method using 2mg DNA and 7ml lipofectamin
(Invitrogen). Transfected cells were rinsed 4h later and incubated
for further 16h before they were used for TEM assay.
Transwell/transendothelial/migration assays
Chemotaxis assays were performed as described previously
(Charbonnier et al, 1999), except that 96-well Transwell plates
(Costar, Cambridge, MA, USA) with 8mm pore size were used and
migrated melanoma cells were collected and measured by Multi-
plate Reader (Paradigm, Beckman Coulter, Fullerton, CA, USA).
Different concentrations of the chemokine solutions or buffer
alone were added to the upper (chemorepulsion) or to the lower
chamber (chemotaxis) to individual wells or to both chambers for
checkerboard analysis. For the TEM assay, the filters were pre-
coated with 10mgml
 1 fibronectin (Sigma) or 1% gelatine (Sigma)
on the upper site. Endothelial cell-monolayers and melanoma cells
were cultivated in medium with 1% FCS with or without CXCL9 for
8h before melanoma cells (Cell Tracker-568) were allowed to
migrate for 8 or 14h.
Chemokinesis assay was performed by using the Oris Cell
Migration Assay from Platypus Technologies (Madison, WI, USA),
utilises cell seeding stoppers to create a pristine, 2mm diameter
detection zone in the centre of each well. Melanoma-7 cells (30000)
were dispensed into each well of a 96-well microplate populated
with the cell seeding stoppers, and incubated for 24h before the
stoppers were removed and cells either non-treated or treated with
soluble chemokine CXCL9 in a concentration-dependent manner.
After migration for 16h, cells were stained with Cell Tracker-488
(Molecular Probes), and the Oris Detection Mask was applied to
the bottom of the microplate. Cells that have migrated into the
detection zone are imaged with the Multiplate Reader.
Flow cytometric analysis
For FACScan, cells (2 to 4 10
5) were either fixed and
permeabilised (Fix & Perm Reagents, Invitrogen) or not fixed
and resuspended in PBS, 0.1% BSA (Biological Industries, Kibbutz
Beil, Haemek, Israel). Immunofluorescence was performed by
exposing cells to antibodies (see Biochemicals and Antibodies) or
Isotype IgG (Sigma-Aldrich) as negative control for 30min on ice
and to 1mgml
 1 propidium iodide (Sigma, 1:100) to gate out dead
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CellQuest software (BD Biosciences).
Electrical cell-substrate impedance sensing technology
Endothelial cell-monolayer breakdown (transmigration) assay was
performed using the electrical cell-substrate impedance sensing
(ECIS) model 1600R (Applied BioPhysics, Troy, NY, USA). The
measurement system consists of an eight-well cell culture dish
(8W10E plate) containing a small active electrode (5 10
 4cm
2)
and a large counter electrode (0.15cm
2) deposited on the bottom
of each well. A small amplitude AC signal is imposed across the
pair of electrodes, onto which cells are deposited. The resulting
impedance is being calculated by the ECIS device (Wegener et al,
2000). For the EC monolayer breakdown assays, 2 10
5 human
LECs were grown to confluent monolayers and treated with
different concentrations of CXCL9 with or without anti-CXCL9 or
anti-CXCR3 antibody for 1h. Melanoma cells (1 10
5) were seeded
on top of the EC-monolayers and EC breakdown was assessed by
continuous resistance measurements for 8–10h.
Immunostaining and immunohistochemistry
Melanoma cells, either co-cultured with human ECs or alone were
seeded into fibronectin-coated (10mgml
 1; Sigma) chamber slides.
After 24h, cells were fixed with 4% paraformaldehyde in PBS for
15min and permeabilised with 0.1% Triton X-100 in PBS for 3min.
Proteins were immunodetected with 5mgml
 1 monoclonal anti-
CXCR3 antibody (Alexa-488), 10mgml
 1 anti-CD144 (Alexa-633),
and phalloidin-568 (Molecular Probes). Chamber slides were
mounted onto coverslips in 60% glycerol-Tris-buffered saline, and
viewed under a confocal microscope (LSM 510, Zeiss, Oberkochen,
Germany). Five-micrometre cryosections of normal skin or metastatic
melanoma were mounted onto glass slides, air-dried, and fixed with
acetone for 20min. After drying, slides were hydrated with Ca2/Mg2-
deficient PBS and exposed to anti-CXCL9 antibody (Isotype-matched
control antibodies), anti-CD144 following Alexa-488, Alexa-633 and
phalloidin-568 exposure.
For the EC monolayer breakdown assay, 2 10
5 HUVECs were
grown to confluent monolayers in fibronectin-coated (10mgml
 1;
Sigma) chamber slides and stimulated with 400ng CXCL9 for
30min. Melanoma-7 cells (3 10
5) were seeded on the monolayer
and endothelial breakdown was allowed for 6h at 371C. Chambers
were fixed and stained with 3mgml
 1 anti-CD31 antibody.
Statistical analysis
The Student’s paired t-test was used, when the data were normally
distributed. Reported P-values are two-tailed, and Po0.05 was
considered statistically significant and Po0.01 was considered as
statistically highly significant. The MFI values were obtained by
subtracting the MFI of the isotype control from the MFI of the
positively stained sample.
RESULTS
Expression of chemokine receptors in freshly isolated
metastatic human melanoma cells
Freshly isolated human melanoma cells, obtained from metastatic
melanoma patients, were isolated and cultivated for a few passages
or used directly (primary melanoma T14, T15) for binding of
antimelanoma antibodies (Melanin A, Tyrosinase, HMB45).
Positive cells were subsequently used to determine expression of
various chemokine receptors (CCR1-CCR9 and CXCR1-CXCR6) in
fixed and permeabilised melanoma cells by flow cytometry
(Supplementary Tables I and II). As such, we could detect
expressions of CCR5, CCR9 and CXCR3 in all malignant metastatic
melanoma cells, using a immunohistochemistry protocol described
previously (Robledo et al, 2001). Moreover, we confirmed the
expression of the CXCR3 receptor on the surface of living
melanoma cells by flow cytometry (Figure 1A). To study the
cellular distribution of this receptor, melanoma cells (Mel-7 and
Mel-15) were grown on fibronectin-coated chamber slides for 24h,
fixed, permeabilised and immunostained with anti-CXCR3
antibody (Alexa-488) and phalloidin-568 (Figure 1B). Alterna-
tively, the melanoma cells were co-cultivated with human ECs,
stained with anti-CXCR3 (Alexa-488) and anti-CD144 (Alexa-633)
antibodies and subsequently investigated using confocal laser
scanning microscopy (Figure 1C). Both flow cytometric and
immunofluorescence microscopic analysis confirmed CXCR3
expression and demonstrated that the receptor is mainly localised
in the cytoplasm, although it can also be found in the plasma
membrane. Moreover, CXCR3 expression is higher in melanoma
cells than in ECs (Figure 1C). To assess whether CXCR3 is also
expressed by melanoma cells in metastatic tumour tissues, we
performed immunofluorescence and confocal microscopy from
normal skin and melanoma metastases, using anti-CXCR3
(Alexa-488) antibody, anti-CD144 (Alexa-633) antibody and phallo-
idin-568. Analysis of lymph node metastases revealed high expression
of CXCR3 in melanoma cells (Figure 1D), which could also be
observed in ECs isolated from both normal skin and tumour tissue.
Taken together, these data demonstrate that human melanoma cells
express the chemokine receptor CXCR3 not only within the tumour
tissue, but also even after isolation and cultivation.
Expression of CXCL9 in TuECs
As our previous results had shown a prominent expression of the
CXCR3 chemokine receptor in human melanoma metastases, we
subsequently wanted to determine whether also the CXCR3 ligands
are expressed in melanoma metastases, by means of performing
immunofluorescence and confocal microscopy of melanoma cells
isolated from normal skin and melanoma metastases, using anti-
CXCL9 (Alexa-488) antibody, anti-CD144 (Alexa-633) antibody
and phalloidin-568. As such, we observed that CXCL9 is highly
expressed in TuECs, especially in their luminal (apical) side of the
tumour vessel (Figure 2A). To further confirm that TuECs express
high levels of CXCR3 ligands, we isolated LECs and blood
endothelial cells (BECs) from normal human skin and TuECs
from melanoma metastases and compared the expression levels of
CXCL9 and CXCL10 using RT–PCR. We could not detect
podoplanin-positive ECs (lymphatic TuECs) in suspensions of
melanoma lesions, although this population made up 40–60% of
total ECs in normal skin (Supplementary Figure 2). Consequently,
only a single population of TuECs was isolated from tumour
samples. Tumour endothelial cells demonstrated a more than
11-fold increase in CXCL9 mRNA expression and a 3- to 20-fold
increase in CXCL10 mRNA expression, as compared with BECs or
LECs in all samples (Figure 2B and C). Samples used were isolated
from patients who did not receive IFN-a or IFN-g treatment for at
least 1 month. Taken together, these results show that TuECs
express high levels of the CXCR3 ligands CXCL9 and CXCL10.
The CXCR3 ligand CXCL9 can induce spontaneous
melanoma cell migration
To better understand the relevance of the overexpression of the
chemokine CXCL9 in TuECs, we have examined in the following
experiments several migratory steps deemed to be important for
metastasis, including migration, endothelial cell–cell breakdown
and TEM. To determine whether CXCL9 can induce chemoattrac-
tion of melanoma cells, three different melanoma cell lines were
stained with Cell Tracker-568, resuspended in migration buffer
and placed into the upper chamber of 96-well Transwells.
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tions (0–400ngml
 1) of the chemokine CXCL9 in the buffer
(Figure 3A). Migration was allowed for 8h, after which cells in the
lower part of the filter were collected and measured in a Multiplate
Reader. As such, we found that CXCL9 is able to trigger a chemotactic
response on all analysed cell lines, with the highest migration detected
at 50ngml
 1 soluble CXCL9, followed by 25 and 100ngml
 1
(Figure 4A). These results are consistent with the ones from previous
studies (Robledo et al, 2001; Kawada et al, 2004).
To investigate whether melanoma cells can also be repelled by
this chemokine, Transwell assays were performed as described
above, except that the soluble chemokine was added to the upper
buffer (Figure 3B). As such, we detected that 200 and 400ngml
 1
of soluble CXCL9, when added to the upper chamber, resulted
in a highly significant fugetactic migration of Melanoma-7
(200ngml
 1: 2.71±0.52; 400ngml
 1: 2.16±1.03), Melanoma-17
(200ngml
 1:3 . 2 5 ±1.10; 400ngml
 1:4 . 0 8 ±1.12) and Melanoma-14
cells (200ngml
 1: 4.12±0.53; 400ngml
 1 3.06±1.08). Soluble
CXCL10 at concentrations of 200 and 400ngml
 1 had a tendency
to induce chemorepulsive migration, albeit not significant (data
not shown). None of the treatments with 0–400ngml
 1 CXCL9 or
CXCL10 influenced cell death or cell proliferation in melanoma
cells (data not shown).
To examine whether the melanoma cells migrate directionally
(along or away a chemogradient) or randomly (chemokinesis), the
Oris Cell Migration Assay was preformed, as described in Materials
and Methods. Melanoma-7 cells were plated around cell seeding
stoppers for 24h before stoppers were removed. Cells (labelled by
Cell Tracker-488) were treated with 0–400ngml
 1 CXCL9, and the
degree of migration into the detection zone was assessed by
measuring the fluorescence intensity after 16h (Figure 3C). CXCL9
revealed a dose-dependent increase of fluorescence (migrated
melanoma cells) in the detection zone. The highest chemokinesis
was detected when Mel-7 cells were stimulated with 200ngml
 1
soluble CXCL9 (2.13±0.48) followed by 400ngml
 1 (1.98±0.29).
To further discriminate between haptotaxis, chemotaxis and
Melanoma-17 HeLa
Melanoma-3 Melanoma-14
Melanoma-15 Melanoma-7
C
o
u
n
t
s
CXCR3-alexa-488
CXCR3 Phalloidin Merge
M
e
l
-
7
CXCR3 + CD144
M
e
l
-
1
5
Normal skin
C
X
C
R
3
P
h
a
l
l
o
i
d
i
n
C
D
1
4
4
M
e
r
g
e
140
120
0
140
0
100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
100 101 102 103 104
60
50
40
30
20
10
0 0
120 50
40
30
20
10
0
100
80
60
40
20
0
50 m
50 m
Tumour
50 m
Figure 1 Expression of CXCR3 on human melanoma cells. (A) Human melanoma cells isolated from melanoma metastases were stained for surface
CXCR3 and analysed by flow cytometry. Grey and bold histogram, CXCR3 staining; black or spotted histogram, isotype staining. (B) Melanoma-7 were
immunostained with anti-CXCR3 antibody, Alexa488-conjugated anti-mouse as secondary reagent, and for actin with phalloidin-568 and viewed by confocal
laser scanning microscopy; bar represents 50mm. (C) Melanoma-15 was co-cultured with HUVECs and stained with anti-CXCR3 (Alexa-488) and anti-
CD144 (Alexa-633) antibodies; bar represents 50mm. (D) Immunolocalisation of CXCR3 in human skin and melanoma metastasis. Cryosections of human
skin and melanoma metastasis were stained with anti-CXCR3 antibody (Alexa-488), anti-CD144 antibody (Alexa-633) and phalloidin-568.
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anti-CD144 antibody (Alexa-568), and phalloidin-568 and viewed by confocal laser scanning microscopy; bar represents 50mm. Insert indicates tumour
vessel in a higher magnification (dotted structure). (B, C) Quantitative Real-time PCR of CXCL9 and CXCL10. Blood ECs, LECs and TuECs were isolated
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transcribed and corresponding cDNA subjected to TaqMan PCR using commercial probes and primers for CXCL9 and CXCL10. All data shown are mean
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T, malignant melanoma).
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schemorepulsion, checkerboard analysis was performed by adding
various concentrations of the soluble chemokine to the upper and
to the lower buffer to individual wells of the Transwell system
(Figure 3D). The highest Mel-7 migration was detected when
200ngml
 1 of soluble CXCL9 was added in the upper chamber,
and 50ngml
 1 (200/50ngml
 1) in the lower chamber (3.2±0.31),
followed by 200/200ng/ml
 1 (3.1±0.41) and 50/50ng (2.9±0.57).
These data confirm that CXCL9 promotes random melanoma cell
migration with the tendency of the melanoma cells to migrate away
from the chemogradient (chemorepulsion) at high concentrations.
Soluble CXCL9 and CXCL9-expressing ECs increase TEM of
melanoma cells
To further determine whether the activating effect of CXCL9
promotes TEM of melanoma cells, HUVECs were cultivated on
fibronectin-coated 8mm filters of a Transwell plate until reaching
confluence, after which the assay was performed as described
above (Figure 4A). Migration was allowed for 16h, after which
melanoma cells were collected and measured in the Multiplate
Reader. The chemotactic repulsion and the subsequent TEM
were stimulated by soluble CXCL9 in a dose-dependent manner
(Figure 4A). Under these conditions, the highest migration
through the EC monolayer could be found at 200ngml
 1 soluble
CXCL9. The highest chemotactic migration and subsequent TEM
were found at 100ngml
 1 soluble CXCL9 (data not shown). These
data indicate that CXCL9 not only promotes chemotaxis towards,
but also chemorepulsion or chemokinesis away from a chemo-
gradient, leading to the subsequent migration of melanoma cells
through an EC monolayer.
To determine whether CXCL9-expressing ECs promote the TEM
of melanoma cells, HUVECs were either transfected with pIRES-
EGFP-CXCL9 plasmid, mock transfected or non-transfected and
subsequently seeded onto fibronectin-coated Transwell culture
chambers until confluent monolayers were formed. Transmigra-
tion of Melanoma-7 cells (Cell Tracker-568) through monolayers
with 15 or 25% CXCL9-transfected, 18% mock-transfected or non-
transfected HUVECs (transfection efficiency defined by FACS
analysis (EGFP-positive cells)) was allowed for 8h. As shown in
Figure 4B, CXCL9 expression in ECs increased the number of
melanoma cells migrating through the HUVEC monolayer 2.5-fold
when 15% ECs expressed CXCL9 or 4.2-fold when 25% of ECs
expressed CXCL9, whereas mock transfection showed no effect.
Similar results were obtained when human LECs (instead of
HUVECs) were transfected with pIRES-EGFP-CXCL9 plasmid,
mock-transfected or non-transfected and seeded onto gelatin
(1%)-coated Transwell culture chambers. Transendothelial migra-
tion was enhanced two-fold if CXCL9 was expressed (Figure 4C).
All the culture conditions were performed in quintuplicate. Almost
all migrated melanoma cells have been found on the underside of
the filter. Taken together, these results indicate that CXCL9
expression in ECs promotes TEM of melanoma cells.
CXCL9 activates melanoma cell migration, resulting in an
enhanced EC monolayer breakdown during melanoma
infiltration
To study the influence of CXCL9 expression on endothelial barrier
function during melanoma cell attachment and infiltration, we
used the ECIS technology (Figure 5A). Endothelial cell monolayer
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Figure 3 CXCL9 induces chemoattraction, chemorepulsion and chemokinesis in melanoma cells. Melanoma cells were assayed for chemoattraction and
chemorepulsion in response to CXCL9 added either to the lower (chemoattraction) or to the upper (chemorepulsion) chamber of the 96-well Transwells.
(A) Chemotactic response of Mel-7, -17 and -14 towards (chemoattraction) soluble CXCL9 or away (chemorepulsion) the soluble chemokine CXCL9 (B)
was probed in the concentrations 0–400ngml
 1.( C) Melanoma-7 were seeded on 96-well plate populated with cell seeding stoppers. After 24h, the cells
adhered to the surface around the stopper tips. Stoppers were removed and melanoma cells were treated with 0–400ngml
 1 soluble CXCL9 and allowed
to migrate (chemokinesis) into the empty space for 16h before cells were stained with Cell Tracker-488, and cells that have migrated into the detection
zone are imaged using the Detection Mask and the Multiplate Reader. (D) Mel-7 cells were assayed for haptotaxis, chemotaxis and chemorepulsion in
response to CXCL9 added to the upper and to the lower chamber of the 96-well Transwells. Mean migration indices (þs.d., nX5 experiments) are given
on the Y axis (*Po0.05; **Po0.01, Student’s t-test).
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sdisruption can thus be monitored online, by means of measuring
the decrease in impedance over time. As such, substances that
influence the infiltration of cells into an EC monolayer can be
detected, as they will lead to a changed resistance of the
monolayer. Lymphatic endothelial cells were cultured onto ECIS
arrays and formed a confluent monolayer within 24h (Figure 5A–E).
The monolayers were pretreated with 0, 100, 200 or 400ngml
 1
soluble CXCL9, before being challenged with Mel-7, Mel-17 and
Mel-14 cells or remaining unchallenged (Figure 5B, grey lines).
Endothelial barrier function was subsequently assessed by
continuous resistance measurements. CXCL9 increased the EC
monolayer disruption during melanoma infiltration in all three
primary melanoma cells in a concentration-dependent manner,
(Figure 5B). No change in resistance could be detected when
monolayers were stimulated with CXCL9 itself or with substances
secreted by melanoma cells, contained in the supernatant (Figure
6Aa and b, Supplementary Figure 1A). When Mel-7 cells were
pulsed for 1h with 200ngml
 1 soluble CXCL9 and subsequently
washed before overlaying them onto the EC monolayer, EC
breakdown was increased, in comparison with non-pulsed cells
(Supplementary Figure 1B). Penetration of melanoma cells could
be significantly decreased when CXCL9 was preincubated with
anti-CXCL9 antibody (Figure 5C) or when the melanoma cells were
treated with anti-CXCR3 antibody for 1h (Figure 5D) before the
challenge of the EC monolayer. These results show that CXCL9
promotes not only the migration (Figure 3), but also the
penetration of melanoma cells through the EC monolayer,
resulting in an enhanced breakdown of the latter.
The soluble chemokine CXCL9 promotes cell–cell
disruption in endothelial monolayers during TEM
To further investigate the influence of soluble CXCL9 during
endothelial breakdown and to detect whether the melanoma cells
were able to form holes, which could be due either by increased
endothelial apoptosis/necrosis and/or by cell–cell contact disrup-
tion during transmigration in the endothelial monolayers,
HUVECs were grown to confluence and were subsequently
stimulated with 200ngml
 1 soluble CXCL9. Thirty minutes later,
the HUVEC monolayer was challenged with Mel-7 cells, after
which endothelial breakdown was allowed to occur for 6h, before
cells were fixed and stained with anti-CD31 antibody (Figure 6A).
When cells were preincubated with soluble CXCL9, melanoma cell
infiltration led to increased hole formation and to complete
monolayer disruption (Figure 6Ac and d). When measuring the
fields that were still occupied with HUVECs, we found that
stimulation with soluble CXCL9 increased the disruption of the
monolayer after melanoma treatment, whereas CXCL9 treatment
by itself had no effect (Figure 6B). To find out whether this effect is
triggered by apoptosis, necrosis or simply by endothelial cell–cell
contact disruption, a migration assay was performed as described
above, in which cells were stained with AnnexinV/PI and measured
in the Multiplate Reader (Figure 6C). Neither apoptosis nor
necrosis could be detected, not even when the endothelial
monolayer was preincubated with CXCL9. In agreement with
Mierke et al (2008), these findings suggest that the melanoma cells
infiltrated not by triggering apoptosis or necrosis in ECs, but
rather by disrupting the endothelial cell–cell contacts.
DISCUSSION
Solid tumours are organ-like structures, containing both malig-
nant tumour and stroma cells, which contain extracellular matrix
and different extracellular molecules, such as growth factors,
adhesion molecules and chemokines. All of these components in
the tumour stroma have a strong influence on tumour cell
proliferation, invasion and metastasis (Aznavoorian et al, 1990;
Ohtani, 1998; Balkwill and Mantovani, 2001; Bissell and Radisky,
2001). Chemokines and chemokine receptors, secreted either by
the tumour cells themselves or by stroma cells, are often strongly
** **
*
3.5
3
2.5
0 ng
M
i
g
r
a
t
i
o
n
 
i
n
d
e
x
2
1.5
1
0.5
0
CXCL9
18% Transfected HUVECs
4
Upper buffer
M
i
g
r
a
t
i
o
n
 
i
n
d
e
x
3
2
1
0
Non-
transfected
Non-
transfected
pIRES-EGFP-
mock
pIRES-EGFP-
mock
pIRES-EGFP-
CXCL9
pIRES-EGFP-
CXCL9
pIRES-EGFP-
CXCL9
**
2.5
2
1.5
1
0.5
0
M
i
g
r
a
t
i
o
n
 
i
n
d
e
x
400 ng 200 ng 100 ng 50 ng
25% 15%
Figure 4 Soluble CXCL9 and CXCL9-expressing ECs increase mela-
noma cells migration through an EC monolayer. (A) Melanoma-7 cells (Cell
Tracker-568) were seeded in the upper chamber and allowed to migrate
through the LEC monolayer and 8-mm pore-size filters for 8h and were
measured by Multiplate Reader. (B) Human umbilical vein endothelial cells
(HUVECs) were transfected with CXCL9 expression constructs (pIRES-
EGFP-CXCL9), mock transfected or non-transfected and seeded on
fibronectin-coated Transwell chambers for 24h (monolayer formation).
Mel-7 cells were seeded in the upper chamber and allowed to attach and
migrate through the HUVEC monolayer and 8-mm pore-size filters for 8h.
The percentage of transfected HUVECs were defined by FACS (EGFP-
positive cells) analysis. (C) Human LECs were transfected (20%
transfection efficiency) as described in B and seeded on gelatine-coated
Transwell chambers for 24h before Mel-7 cells (Cell tracker-568) were
allowed to attach and migrate through the EC monolayer for 14h. Migrated
melanoma cells in the lower part of the filter and in the fluid phase of the
lower chamber were gathered and relative fluorescence detected by
Multiplate Reader (*Po0.05; **Po0.01, Student’s t-test).
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supregulated during tumourigenesis, can lead to increased angio-
genesis and tumour growth, to the stimulation of the immune
response to the tumour and to the facilitation of metastasis (Wang
et al, 1998; Payne and Cornelius, 2002; Kakinuma and Hwang,
2006; Raman et al, 2007). In this report, we have demonstrated that
the chemokines CXCL9 and CXCL10 are highly expressed in
TuECs. We also found that the receptor for these ligands, that is,
the CXCR3 protein, was expressed in all isolated, living melanoma
cells. CXCR3 expression in human and murine melanoma cell lines
has been suggested by others to mediate directional cell migration
along the chemokine gradients of CXCL9, CXCL10 and CXCL11
(Robledo et al, 2001; Kawada et al, 2004). The results presented in
this study demonstrate that CXCL9 secreted by TuECs triggers
different types of directional migration, that is, chemotaxis,
fugetaxis and chemokinesis in melanoma cells in a concentra-
tion-dependent manner. This chemorepellent signal has been
described first by Vianello et al (2005), who reported that mature
single-positive CD4 cells emigrate from the fetal thymus on
treatment with high concentrations of CXCL12/SDF-1, by means of
concentration-dependent and CXCR4 receptor-mediated fugetaxis
(Vianello et al, 2005, 2006). In this report, we show for the first
time that high concentrations of the soluble chemokine CXCL9
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Figure 5 CXCL9 promotes EC monolayer disruption and melanoma cell invasion in a concentration-dependent manner. (A) Schematic diagram of the
ECIS technology adapted for the EC monolayer disruption assay. (B) Lymphatic endothelial cells were seeded onto ECIS arrays and allowed to grow to a
monolayer before treated with different concentrations of soluble CXCL9 or not treated and challenged with melanoma cells (Mel-7, -17, -14) 1h later.
Endothelial cell monolayer breakdown during melanoma cell transmigration was assessed by continuous resistance measurements for 5–10h. (C) Same
approach as in B, except that the 200ngml
 1 CXCL9 was preincubated with anti-CXCL9 antibody for 1h before the monolayer was overlaid with
Mel-7 cells. (D) Same approach as in C, except that melanoma cells were preincubated with anti-CXCR3 antibody for 1h.
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spreferentially promote chemokinesis and the chemorepulsive
migration of human melanoma cells rather than the movement
towards the chemogradient (Figure 3).
In our in vitro studies reported here we could further
demonstrate that soluble CXCL9 promotes the migration of
melanoma cells through an EC monolayer in a dose-dependent
manner. Although the chemokines CXCL9, CXCL10 and CXCL11
were reported to have an angiostatic effect when expressed by
melanoma cells (Romagnani et al, 2001a,b; Mehrad et al, 2007;
Keeley et al, 2008), our study suggests that the chemokine CXCL9
may promote additional metastasis, when it is expressed in TuECs,
by means of increasing transendothelial and melanoma migration.
In this report, we demonstrate that the CXCL9/CXCR3 interaction
exhibits a strong chemotactic efficacy for melanoma cells, not only
in chemotactic migration but also in fugetaxis as well as in TEM,
processes that are crucial for the dissemination of melanoma cells
and for the further establishment of novel melanoma metastases.
It was suggested that in tumours the cancer cells are often
integrated into the vessel wall, making tumour vessels leaky
or causing complete disruption of the endothelial barrier
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Figure 6 CXCL9 enhances cell–cell disruption during melanoma cell infiltration. (A) Human umbilical vein endothelial cell (HUVEC) monolayers were
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s(Stewart et al, 1987; Hashizume et al, 2000; Heyder et al, 2002). We
used the sensitive and reproducible ECIS technology to monitor
endothelial monolayer integrity during melanoma cell infiltration
in real time, and measured the influence of different soluble
CXCL9 concentrations. As expected from the TEM assays, the
addition of soluble CXCL9 significantly accelerated melanoma-
mediated breakdown of the EC monolayer in a concentration-
dependent manner. In addition, we were able to confirm that this
increased EC monolayer breakdown was not mediated by binding
of CXCL9 ligand to the CXCR3 receptor presented by ECs, but due
to the ligand/receptor interaction on melanoma cells. This was also
confirmed by the fact that the monolayer breakdown was blunted
when the soluble chemokine was neutralised with anti-CXCL9
antibody or when the melanoma cells were pretreated with anti-
CXCR3 antibody.
These findings suggest that CXCL9-activated melanoma cells
reinforce the leakiness of the tumour vessels, which may lead to
increased intravasation and dissemination of the melanoma cells.
Immunostaining experiments revealed that upon CXCL9 stimula-
tion, melanoma transmigration led to the formation of ‘holes’ in
the endothelial monolayer and subsequently to the complete EC
monolayer disruption. In contrast to several reports, we found no
indication of triggering of the ECs towards apoptosis or necrosis
during the TEM of the melanoma cells, suggesting that the
breakdown of the endothelial monolayer is caused by the
disruption of the cell–cell contacts (Li et al, 2001; Heyder et al,
2002; Lasagni et al, 2003; Mierke et al, 2008).
As a result of our study, one could argue that CXCL9 expressed
by tumour stroma cells promotes the escape of the melanoma cells
from tumour metastases. On the one hand, the chemokine CXCL9
has been described as a key mediator in homing and metastasis,
as confirmed by the fact that expression of CXCL9 and CXCL10 in
the lymph nodes facilitates melanoma cell metastasis in a murine
model (Kawada et al, 2004). By contrast, however, it was
demonstrated that the application of chemokines and cytokines,
either together with chemotherapy or as an alternative, can be
beneficial for the treatment of malignancies in experimental
animal models (Sgadari et al, 1997; Kanegane et al, 1998; Rodolfo
and Colombo, 1999; Clinton et al, 2000; Keilholz and Eggermont,
2000). Owing to the fact that the treatment of melanoma
metastases with interferon-a or interferon-g alone or in combina-
tion with dacarbazine (or other chemotherapeutic) shows only
little or no significant difference in median survival or overall
response rate (Shepherd and Milne, 2000), it might be possible that
the melanoma cells overcome the antitumour effect by exploiting
the high CXCL9 expression to escape from the tumour and to form
novel metastases at distant sites.
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